Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 May 9;213(3):329–341. doi: 10.1083/jcb.201506140

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 Rao et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 4. — Ninein siRNA treatment leads to increased MT sliding in the leading process of migratory neurons. (A) A cerebellar migratory neuron transfected with tdEos-tubulin. (top) A distinguished converted region in the leading process of a neuron treated with control siRNA. Leading process is magnified on the right. (bottom) After 5 min, individual MTs (indicated by the arrow) are observed sliding out of the converted region. (B, top) Migratory neuron treated with control siRNA. Modest signal decay is observed after 15 min. (middle) After treatment with ninein siRNA, significant signal decay can be seen. (bottom) Treating ninein-depleted migratory neurons with FCPT reduces the rate of signal decay to control levels. (C) Quantification of percent decay of fluorescent tubulin signal. Data table shows values under control siRNA (n = 15), ninein siRNA (n = 15), and ninein siRNA + FCPT conditions (n = 15 per group; *, P < 0.05). Bars, 10 µm. Data are represented as mean ± SEM.